Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI.

J Clin Oncol. 2009 May 20;27(15):2436-42. doi: 10.1200/JCO.2008.20.4164. Epub 2009 Apr 13. Erratum in: J Clin Oncol. 2011 Oct 10;29(29):3947-8.

2.

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ.

Cancer. 2013 Sep 1;119(17):3186-94. doi: 10.1002/cncr.28103. Epub 2013 Jun 13.

3.

Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.

Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, Deweese T, Eisenberger MA.

Urol Oncol. 2011 Nov-Dec;29(6):670-5. doi: 10.1016/j.urolonc.2009.10.003. Epub 2009 Dec 4.

4.

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.

Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ.

J Clin Oncol. 2009 Jul 10;27(20):3319-24. doi: 10.1200/JCO.2008.20.5393. Epub 2009 May 4.

5.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A.

J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13.

PMID:
19364971
6.

Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.

Higano CS, Quick DP, Bushnell D, Sartor O.

Clin Genitourin Cancer. 2008 Mar;6(1):40-5. doi: 10.3816/CGC.2008.n.007.

PMID:
18501082
7.

Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.

Borsò E, Boni G, Pastina I, Lorenzoni A, Cianci C, Federici F, Mazzarri S, Orlandini C, Francesca F, Selli C, Ricci S, Rubello D, Mariani G.

Nucl Med Commun. 2014 Jan;35(1):88-94. doi: 10.1097/MNM.0000000000000023.

PMID:
24157942
8.

Biodistribution of samarium-153-EDTMP in rats treated with docetaxel.

Villarim Neto A, Açucena MK, Pereira KR, Rêgo AC, Azevedo IM, Bernardo-Filho M, Medeiros AC.

Acta Cir Bras. 2009 Jan-Feb;24(1):62-6.

9.

A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.

Valicenti RK, Trabulsi E, Intenzo C, Lavarino J, Xu Y, Chervoneva I.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):732-7. doi: 10.1016/j.ijrobp.2009.11.011. Epub 2010 Apr 14.

PMID:
20399029
10.

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C.

J Clin Oncol. 2004 Aug 15;22(16):3323-9.

PMID:
15310776
11.

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ.

Cancer. 2012 Jan 1;118(1):63-71. doi: 10.1002/cncr.26204. Epub 2011 Jul 25.

12.

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.

Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G.

Urol Oncol. 2013 May;31(4):436-41. doi: 10.1016/j.urolonc.2011.02.007. Epub 2011 Apr 11.

13.

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.

Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.

Urology. 2005 Jan;65(1):126-30.

PMID:
15667877
14.

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ.

Clin Cancer Res. 2008 Oct 1;14(19):6270-6. doi: 10.1158/1078-0432.CCR-08-1085.

15.

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI.

Cancer Chemother Pharmacol. 2010 May;66(1):181-9. doi: 10.1007/s00280-010-1289-x. Epub 2010 Mar 9.

PMID:
20217089
16.

Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?

Waldert M, Klatte T, Remzi M, Sinzinger H, Kratzik C.

World J Urol. 2012 Apr;30(2):233-7. doi: 10.1007/s00345-011-0685-0. Epub 2011 May 11.

PMID:
21559805
18.

Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.

Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ.

Clin Nucl Med. 2013 Feb;38(2):88-92. doi: 10.1097/RLU.0b013e318279bf4d.

PMID:
23334120
19.

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ.

Clin Genitourin Cancer. 2007 Jun;5(5):323-8.

PMID:
17645829
20.

Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.

Tester W, Ackler J, Tijani L, Leighton J.

Cancer J. 2006 Jul-Aug;12(4):299-304.

PMID:
16925974

Supplemental Content

Support Center